Nov 23 (Reuters) - Glaxosmithkline Plc :
* Mepolizumab meets endpoints in phase 3 egpa study
* Phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis
* Mepolizumab is not approved for use anywhere in world for EGPA.
* Will support GSK’s plans to submit regulatory applications for this patient population, expected in 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)